Premium
The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation
Author(s) -
Graaf Y.G.L.,
Basdew V.R.,
ZwanKralt N.,
Willemze R.,
Bouwes Bavinck J.N.
Publication year - 2006
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.07069.x
Subject(s) - medicine , curettage , surgery , electrosurgery , dermatology
Summary Background Organ transplant recipients frequently develop multiple squamous cell carcinomas (SCCs). Surgical excision and Mohs micrographic surgery are frequently used treatments for these carcinomas; however, curettage and electrodesiccation are a useful alternative in these patients. Objectives To evaluate the efficacy of curettage and electrodesiccation for the treatment of appropriately selected low‐risk SCCs in organ transplant recipients at different sites. Methods Between April 1989 and December 2004, 211 SCCs in 48 organ transplant recipients were treated by curettage and electrodesiccation. Only histologically confirmed SCCs were considered in this study. The charts of these patients were retrospectively reviewed and checked for the rate of residual or recurrent SCCs. The occurrence of residual or recurrent SCCs at different locations after treatment of SCCs with curettage and electrodesiccation was estimated with Kaplan–Meier survival analysis. Results The mean follow‐up time after curettage and electrodesiccation of the individual SCCs was 50 months (median 41; range 3–186). In total, 13 residual or recurrent SCCs were observed in 10 patients. The overall rate of residual or recurrent SCCs was 6%, with 7% for SCCs on the dorsum of the hands or fingers, 11% for SCCs on the head and neck, 0% for the forearms, and 5% for the remaining nonsun‐exposed areas (shoulder, legs). No major clinical or cosmetic adverse events were registered after treatment. Conclusions In organ transplant recipients with many SCCs curettage and electrodesiccation can be a safe therapy for appropriately selected low‐risk SCCs, with an acceptable cure rate.